|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We selected NSCLC cell lines--A549 (KRAS G12S), NCI-H3255 (EGFR L858R), NCI-H3122 (EML4-ALK E13;A20), and HCC78 (SLC34A2-ROS1)-to evaluate the antiproliferative effects of submicromolar concentrations of the multitargeted TKIs imatinib, sorafenib, erlotinib, and crizotinib.
|
22617245 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
CausalMutation
|
CLINVAR |
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
|
19358724 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
CausalMutation
|
CLINVAR |
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
|
18794081 |
2008 |
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
CausalMutation
|
CLINVAR |
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
|
18594010 |
2008 |
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
CausalMutation
|
CLINVAR |
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
|
18794081 |
2008 |
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
CausalMutation
|
CLINVAR |
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
|
18794081 |
2008 |
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
CausalMutation
|
CLINVAR |
Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.
|
17704260 |
2007 |
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
CausalMutation
|
CLINVAR |
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
|
15696205 |
2005 |
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
CausalMutation
|
CLINVAR |
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
|
15696205 |
2005 |
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
CausalMutation
|
CLINVAR |
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
|
15696205 |
2005 |
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
CausalMutation
|
CLINVAR |
BRAF and RAS mutations in human lung cancer and melanoma.
|
12460918 |
2002 |
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
CausalMutation
|
CLINVAR |
BRAF and RAS mutations in human lung cancer and melanoma.
|
12460918 |
2002 |
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
CausalMutation
|
CLINVAR |
BRAF and RAS mutations in human lung cancer and melanoma.
|
12460918 |
2002 |
|
Malignant neoplasm of urinary bladder
|
|
0.800 |
GeneticVariation
|
UNIPROT |
|
|
|
|
Malignant neoplasm of urinary bladder
|
|
0.800 |
CausalMutation
|
CLINVAR |
|
|
|
|
Malignant neoplasm of lung
|
|
0.770 |
GeneticVariation
|
BEFREE |
We developed an integrative pharmacogenomics analysis to identify potential drug targets to overcome MEK/ERK inhibitor resistance in lung cancer cell lines with KRAS(G12C) mutation (n = 12).
|
31668570 |
2019 |
|
Malignant neoplasm of lung
|
|
0.770 |
GeneticVariation
|
BEFREE |
Although this mutation in KRAS accounts for 11% of all KRAS mutations in cancer, it is the most prominent KRAS mutant in lung cancer suggesting that G12C-specific inhibitors may provide a new approach for treating the subset of lung cancer patients harboring this mutant allele.
|
30366101 |
2019 |
|
Malignant neoplasm of lung
|
|
0.770 |
GeneticVariation
|
BEFREE |
Adding mTOR and IGF1R inhibitors to ARS-1620 greatly improves its effectiveness on KRAS-G12C mutant lung cancer cells in vitro and in mouse models.
|
31534020 |
2019 |
|
Malignant neoplasm of lung
|
|
0.770 |
GeneticVariation
|
BEFREE |
To substantiate these results, an allitinib-sensitive lung cancer-derived cell line (H292) was transfected with plasmids carrying the two most common activating KRAS mutations (p.G12D and p.G12S).
|
26920031 |
2016 |
|
Malignant neoplasm of lung
|
|
0.770 |
GeneticVariation
|
BEFREE |
Next generation sequencing performed on the Ion Torrent platforms by the Ion Ampliseq Colon and Lung Cancer panel showed a similar genomic profile in both neoplastic sites with a concurrent KRAS G12C mutation.
|
25900221 |
2015 |
|
Malignant neoplasm of lung
|
|
0.770 |
GeneticVariation
|
BEFREE |
Gene-expression profiles in lung cancer cell lines and surgically resected lung AC revealed that KRAS-G12C mutants had an epithelial to mesenchymal transition and a KRAS-independent phenotype.
|
25170638 |
2014 |
|
Malignant neoplasm of lung
|
|
0.770 |
GeneticVariation
|
BEFREE |
Our study demonstrated that TRAIL significantly suppressed cell survival, by inducing apoptosis in a dose-dependent manner, in the pancreatic cancer BxPC-3 (wild type G12) and lung cancer A549 (G12S) cell lines.
|
20848283 |
2011 |
|
Malignant neoplasm of lung
|
|
0.770 |
GeneticVariation
|
UNIPROT |
|
|
|
|
Adenocarcinoma of lung (disorder)
|
|
0.730 |
GeneticVariation
|
BEFREE |
<i>KRAS p.G12C</i>, which occurs in approximately 14% of lung adenocarcinomas, 3-5% of colorectal cancers, and low levels in other solid tumors, represents an attractive therapeutic target for covalent inhibitors.
|
31531201 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
|
0.730 |
GeneticVariation
|
CLINVAR |
Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.
|
25044103 |
2014 |